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Recent evidence suggests that reactive oxygen species (ROS) produced by inflammatory cells drive axonal
degeneration in active multiple sclerosis (MS) lesions by inducing mitochondrial dysfunction. Mitochondria are
endowed with a variety of antioxidant enzymes, including peroxiredoxin-3 and thioredoxin-2, which are involved in
limiting ROS-induced damage. In this study, we explored the distribution and role of the mitochondrial antioxidants
peroxiredoxin-3 and thioredoxin-2 as well as their regulator peroxisome proliferator-activated receptor gamma
coactivator1-alpha (PGC-1α) in MS pathogenesis.
Immunohistochemical analysis of a large cohort of MS patients revealed a striking upregulation of PGC-1α and
downstream mitochondrial antioxidants in active demyelinating MS lesions. Enhanced expression was predominantly
observed in reactive astrocytes. To elucidate the functional role of astrocytic PGC-1α in MS pathology, we generated
human primary astrocytes that genetically overexpressed PGC-1α. Upon an oxidative insult, these cells were shown to
produce less ROS and were found to be more resistant to ROS-induced cell death compared to control cells. Intriguingly,
also neuronal cells co-cultured with PGC-1α-overexpressing astrocytes were protected against an exogenous oxidative
attack compared to neuronal cells co-cultured with control astrocytes. Finally, enhanced astrocytic PGC-1α levels
markedly reduced the production and secretion of the pro-inflammatory mediators interleukin-6 and chemokine (C-C
motif) ligand 2. Our findings suggest that increased astrocytic PGC-1α in active MS lesions might initially function as an
endogenous protective mechanism to dampen oxidative damage and inflammation thereby reducing neurodegeneration.
Activation of PGC-1α therefore represents a promising therapeutic strategy to improve mitochondrial function and
repress inflammation.
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Multiple sclerosis (MS) is the leading cause of non-
traumatic neurological disability among young adults in
Europe and North-America [1]. MS is generally character-
ized as an immune-mediated disease in which infiltrating
macrophages and T-lymphocytes induce focal demyelin-
ation and neurodegeneration by producing large amounts* Correspondence: p.nijland@vumc.nl; Maarten.Witte@med.uni-muenchen.de
†Equal contributors
1Department of Pathology, MS Center Amsterdam, VU University Medical
Center, Amsterdam, The Netherlands
2Department of Molecular Cell Biology and Immunology, Neuroscience
Campus Amsterdam, VU University Medical Center, Amsterdam, The
Netherlands
Full list of author information is available at the end of the article
© 2014 Nijland et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of inflammatory cytokines and reactive oxygen species
(ROS) [2,3]. In the process of inflammation-driven demye-
lination, astrocytes become activated and data is emerging
that reactive astrocytes play an important and dual role in
various processes underlying MS pathogenesis (for review
see [4,5]). Reactive astrocytes can aggravate inflammation
and blood–brain barrier (BBB) leakage by secreting in-
flammatory molecules, but also facilitate BBB repair,
secrete immunosuppressive molecules and possess neuro-
protective properties [6-9]. Importantly, astrocytes are the
main source of antioxidants and are thus essential for
scavenging ROS in MS lesions [10,11].
Macrophages and activated microglia produce sig-
nificant amounts of ROS, which leads to increasedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oxidative stress and mitochondrial dysfunction [12].
ROS-mediated mitochondrial dysfunction is an import-
ant cause for axonal and neuronal degeneration, which
are the pathological substrates of permanent disability in
MS patients [13-15]. Mitochondria continuously pro-
duce ROS and are therefore equipped with a specific
and efficient antioxidant apparatus, which under phys-
iological circumstances efficiently controls the mito-
chondrial redox balance, thereby ensuring adequate
mitochondrial function [16,17]. Peroxiredoxin-3 (Prx3)
is the mitochondria-specific member of the peroxire-
doxin family and catalyzes the reduction of various
peroxides, a reaction in which peroxiredoxins are oxi-
dized [18]. To regain its antioxidant capacity, Prx3 is
reduced by mitochondrial thioredoxin-2 (Trx2), which
by itself is also capable of directly reducing various
ROS and oxidized proteins [19]. Proper function of
Prx3 and Trx2 are of particular importance in the cen-
tral nervous system (CNS) as neurons are highly
dependent on a healthy mitochondrial population. In
fact, different studies have indicated that Prx3 and
Trx2 have neuroprotective properties [20,21].
Recently, we showed that the expression of mitochon-
drial antioxidants is reduced in the cortex of MS pa-
tients compared to control grey matter. Notably, the
observed decrease strongly correlated with a significant
decrease in the levels of transcriptional co-regulator per-
oxisome proliferator-activated receptor gamma co-
activator 1-alpha (PGC-1α) [22]. PGC-1α has multiple
binding partners and is thereby able to simultaneously
induce transcription of a broad set of genes, most of
which are involved in energy metabolism and redox
handling, including Prx3 and Trx2 [23,24]. Thus far, data
on the expression of PGC-1α and mitochondrial anti-
oxidant enzymes in various stages of MS white matter
lesions is limited. However, oxidative stress and mito-
chondrial dysfunction are most prominent in white mat-
ter lesions and contribute to axonal loss [25]. Therefore,
it is imperative to understand and identify potential pro-
tective mechanisms aimed at restoring the redox balance
and improving mitochondrial function in MS lesions.
Hereto, we set out to explore the cellular distribution of
key mitochondrial antioxidants and their transcriptional
regulator PGC-1α in a large set of well-characterized
MS white matter lesions.
We here describe that the expression of mitochondrial
antioxidants and PGC-1α is markedly increased in in-
flammatory white matter lesions, particularly in reactive
astrocytes. Overexpression of PGC-1α in human astro-
cytes reduced astrocytic ROS production and protects
astrocytes from exogenous ROS-induced cell death. More-
over, neurons co-cultured with PGC-1α-overexpressing as-
trocytes are more resistant to exogenous ROS. Interestingly,PGC-1α also reduced interleukin-6 (IL-6) and chemokine
(C-C motif) ligand 2 (CCL2) production by human astro-
cytes under normal and inflammatory conditions. Our
data indicate that increased expression of PGC-1α and
downstream mitochondrial antioxidants in astrocytes in
MS lesions represents an intrinsic defense mechanism to
restore the redox balance, suppress inflammation and




Formalin-fixed, paraffin-embedded brain sections were ob-
tained from 19 patients and 10 matched non-neurological
controls from the Netherlands Brain Bank, Amsterdam
and the Medical University Vienna, Austria. Detailed clin-
ical data are summarized in Table 1. The study was ap-
proved by the institutional ethics review board (VU
University Medical Center, Amsterdam; Medical Univer-
sity of Vienna EK Nr. 535/2004) and all donors or their
next of kin provided written informed consent for brain
autopsy, use of material and clinical information for re-
search purposes.
Immunohistochemistry
Five μm-thick paraffin sections were collected on Super-
frost Plus glass slides (VWR international; Leuven,
Belgium) and dried overnight at 37°C. Sections were pre-
treated and stained as described previously [26]. In
short, sections were deparaffinized in a series of xylene
(3 × 5 min), 100% ethanol, 96% ethanol, 70% ethanol and
water. Endogenous peroxidase activity was blocked by
incubating the sections in methanol with 0.3% H2O2.
Next sections were incubated with appropriate primary
antibodies (see Additional file 1: Table S1) in phosphate
buffered saline (PBS) supplemented with 1% bovine serum
albumin (BSA; Roche diagnostics GmbH, Mannheim,
Germany) overnight at 4°C and stained with the EnVision
horseradish peroxidase (DAKO, Glostrup, Denmark) kit
followed by 3,3′diaminobenzidine-tetrahydrochloridedihy-
drate (DAB; DAKO). After a short rinse in tap water, sec-
tions were counterstained with haematoxylin for 1 min
and intensely washed with tap water for 5 min.
Fluorescence immunohistochemistry in early active
MS lesions was performed on paraffin sections as de-
scribed previously [27]. For confocal fluorescent double
labelling or triple labelling with primary antibodies from
different species, antibodies were applied simultaneously
at 4°C overnight (Additional file 1: Table S1). After wash-
ing with Dako washing buffer (DakoCytomation, Glostrup,
Denmark), secondary antibodies consisting of donkey-
anti-mouse Cy3 (Jackson ImmunoResearch, 1:200), biotinyl-
ated donkey-anti-rabbit (Amersham Pharmacia Biotech;
1:200) and Cy5-conjugated donkey-anti-goat, were applied
Table 1 Clinical data of MS patients and non-neurological controls





MS 1 73 ND m 6:45 26 CIA
MS 2 63 PP m 7:05 25 CA
MS 3 56 SP m 8:00 27 CIA
MS 4 66 ND m 7:45 ND A
MS 5 41 PP m 7:20 14 A, CA
MS 6 49 SP m 8:00 25 CIA
MS 7 66 PP m 7:30 26 2*CA
MS 8 61 SP m 9:15 30 3*CA, CIA
MS 9 44 PP m 12:00 13 CA
MS 10 44 SP m 10:15 22 CA
MS 11 54 PP m 8:15 15 3*A
MS 12 45 AMS m ND 1 week 3*A, CA, CIA
MS 13 35 AMS m ND 6 weeks 5*A, 2*CIA
MS 14 40 RR f ND 10 A
MS 15 34 AMS f ND 0,3 A
MS 16 78 AMS m ND 0,2 A, CA
MS 17 41 SP m ND 10,6 A
MS 18 46 SP f ND 37 CA, CIA
MS 19 51 AMS f ND 0,5 A, 3*CA
Ctrl 1 66 NA f 7:00 NA NA
Ctrl 2 71 NA m 8:55 NA NA
Ctrl 3 58 NA m 5:15 NA NA
Ctrl 4 62 NA m 7:20 NA NA
Ctrl 5 78 NA m 17:40 NA NA
Ctrl 6 51 NA f 5:36 NA NA
Ctrl 7 70 NA m ND NA NA
Ctrl 8 46 NA m ND NA NA
Ctrl 9 37 NA m ND NA NA
Ctrl 10 39 NA f ND NA NA
SP = secondary progressive MS; PP = primary progressive MS; AMS = Acute MS; ND = not determined; NA = non applicable; m =male; f = female; A = active lesion;
CA = chronic active lesion; CIA = chronic inactive lesion.
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by application of streptavidin-Cy2 (Jackson Immuno-
Research; 1:75) for 1 hour at room temperature. Fluorescent
preparations were embedded and examined using a con-
focal laser scan microscope (Leica SP5, Leica Mannheim,
Germany) equipped with lasers for 504, 488, 543 and
633 nm excitation. Scanning for Cy2 (488 nm), Cy3 and
Cy5 was performed sequentially to rule out fluorescence
bleed through.
For colocalization studies in late active lesions, depar-
affinized sections were incubated for 30 minutes with
10% animal serum, of which the source was determined
by the specific secondary antibody used followed by in-
cubation with the primary antibodies (Additional file 1:
Table S1). Alexa Fluor® (Life Technologies, Vienna, Austria)labeled secondary antibodies were used for fluorescent
labeling. Images were taken on a Leica DM6000 micro-
scope (Leica Microsystems Heidelberg GmbH, Mannheim,
Germany). All primary antibodies were diluted in 0.01 mol/
L phosphate buffered saline (PBS; pH 7.4) containing 1%
BSA and 0,05% Tween-20 (SigmaAldrich, StLouis, MO,
USA), which also served as a negative control.
Cell culture and lentiviral-induced (over)expression
Primary human cerebellar astrocytes (ScienCell, Carlsbad,
CA) were cultured in astrocyte medium (ScienCell). The
human neuroblastoma cell line SH-SY5Y and the human
astrocytoma cell line U373 were both cultured in DMEM/
F12 (1:1, Life Technologies) containing 10% foetal calf
serum (FCS, Life Technologies), 2 mM L-glutamin (Life
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Life Technologies) in 5% CO2 at 37°C.
To overexpress Prx3, its coding sequence was amplified
from primary human astrocyte cDNA with primers (for-
ward: CGGATCCCGATGGCGGCTGCTGTAGGA re-
verse: CCGAATTCCTACTGATTTACCTTCTGAAAG)
and cloned into the lentiviral vector pRRL-cPPT-CMV-
X2-PRE-SIN (kindly provided by Dr. J. Seppen, Academic
Medical Center, Amsterdam, the Netherlands). The hu-
man Trx2 plasmid was kindly provided by Professor Jones
(Emory University, Atlanta, GA, USA) and the human
PGC-1α plasmid by Professor Strömstedt (Department of
Pharmaceutical Biosciences, University of Oslo, Norway).
Both vectors were amplified and cloned into the pRRL
lentiviral vector [28,29]. Lentiviral vectors were produced
by co-transfecting subconfluent human embryonic kidney
(HEK) 293 T cells with the Prx3, Trx2 or PGC-1α expres-
sion plasmid and lentiviral packaging plasmids (pMDLg/
pRRE and pRSV-Rev), using calcium phosphate as a trans-
fection reagent. Lentiviral vectors were collected 24 h after
transfection. The supernatant was centrifuged to remove
cell debris and stored at −80°C. Human astrocytes were
transduced with the lentivirus-containing PGC-1α. Hu-
man astrocytes overexpressing PGC-1α are indicated as
PGC-1α+ astrocytes throughout the manuscript. U373
astrocyte-like cells were also transduced with PGC-1α and
with Prx3 or Trx3 containing lentivirus since primary hu-
man astrocytes were scarce. Forty-eight hours after trans-
duction, stable cell lines were selected by puromycin
treatment (2 μg/mL; SigmaAldrich). The overexpression
efficiency was determined by qPCR and western blotting
and stable cell lines were used for functional studies de-
scribed hereafter. Human astrocytes and U373 cells stably
transduced with the empty pRRL vector served as control.
Finally, SH-SY5Y neuroblastoma cells and human astro-
cytes were stably transduced with the SHC003 turboGFP
vector (Sigma Aldrich), to generate a green fluorescent cell
line.
Real-time quantitative PCR
Total RNA from astrocyte cultures was isolated using Tri-
zol (Invitrogen, Carlsbad, CA, USA) according to manu-
facturer’s protocol. mRNA concentrations were measured
using Nanodrop (Nanodrop Technologies, Wilmington,
DE, USA). cDNA was synthesized with the Reverse Tran-
scription System kit (Promega, Madison, WI, USA) follow-
ing manufacturer’s guidelines. Quantitative PCR (qPCR)
reactions were performed in an ABI7900HT sequence de-
tection system using the SYBR Green method (Applied
Biosystems, Foster City, CA, USA) as described previously
[30]. Obtained mRNA expression levels were normalized to
XPNPEP1 (Qiagen, Venlo, the Netherlands) expression
levels, which a recent study found to be the housekeeping
gene of choice in human CNS studies and was in our handsalso the most consistent in human primary astrocytes [31].
All oligonucleotides were synthesized by Ocimum Biosolu-
tions (Ocimum Biosolutions, IJsselstein, the Netherlands)
(Additional file 2: Table S2).
Western blot
Protein isolation from astrocytes was performed using
M-PER buffer supplemented with protease and phos-
phatase inhibitors according to manufacturer’s protocol
(Thermo Scientific, Rockford, IL, USA). Protein concen-
trations were measured using BCA protein assay (Thermo
Scientific). Western blot was performed as described
previously [32]. In short, equal amounts of protein (25-
100 μg) were separated on 10% SDS-PAGE gels and trans-
ferred to PVDF membranes (Bio-Rad Laboratories, Berkeley,
CA, USA). After blocking in Odyssey blocking buffer
(LI-COR Biosciences, Lincoln, AKUSA), membranes were
incubated with appropriate primary antibodies (for details,
see Additional file 1: Table S1) overnight in Odyssey
blocking buffer at 4°C. Primary antibodies were detec-
ted by incubation with appropriate IRDye secondary an-
tibodies (LI-COR Biosciences) for 1 hour at RT in
Odyssey blocking buffer and quantified using the Odyssey
infrared imaging system (LI-COR Biosciences).
Functional analysis of cells overexpressing Prx3, Trx2 and
PGC-1α
Stable cell lines transduced with Prx3, Trx2 and PGC-1α
containing lentiviral vector or empty pRRL vector were
plated in 96-well plates (Greiner Bio-One, Frickenhausen,
Germany) and grown until confluent. Cells were trea-
ted with 200 μM of tbH2O2 for 6 hours. Hereafter, cell
viability was assessed using the LIVE/DEAD Viability/
Cytotoxicity kit (Invitrogen) according to the manufac-
turer’s protocol. Fluorescent signals were measured with
the Fluostar Galaxy (BMG Labtech, Ortenberg, Germany)
fluometer and the ratio between dead and live cells was
calculated. Endogenous ROS production was assessed
using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluores-
cein di-acetate, acetyl ester (CM-H2DCFDA; Invitrogen),
a probe which turns fluorescent upon oxidation. Total
fluorescence was measured with the Fluostar Galaxy
(BMG Labtech, Ortenberg, Germany) and corrected for
live cell number.
Enzyme linked immunosorbent assays (ELISA)
Secretomes of mock and PGC1α + astrocytes treated for
24 hours with or without TNF-α and IFN-γ (5 ng/ml;
Peprotech, UK) were harvested and stored at −80°C for
further analysis. The Human IL-6 Cytoset™ (Invitrogen)
and Human CCL2 DuoSet® (R&D system, Minneapolis,
MN) ELISA kits were used to determine the amount of
IL-6 and CCL2 secreted by primary human astrocytes.
ELISA was performed according to manufactures protocol
Figure 1 (See legend on next page.)
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Figure 1 Increased expression of PGC-1alpha and downstream mitochondrial antioxidants in active MS lesions. MS lesions are
characterized by loss of proteolipid protein (PLP; A). In early active lesions densely packed macrophages containing myelin proteins are present
(B, inset), late active lesions typically contain MHCII positive leukocytes throughout the lesion area (C). Chronic active MS lesions are characterized
by a rim of activated microglia/macrophages at the border of the lesion which are absent in the lesion center (D). Low PGC-1α, Prx3 and Trx2
immunostaining was observed in the NAWM (E-G, insets). Early active lesions showed enhanced PGC-1α, Prx3 and Trx2 immunoreactivity in
astrocytes (arrow) and oligodendrocytes (arrowhead) (H-J, insets). In late active lesion expression is predominantly localized to astrocytes (arrow)
(K-M, insets), which was largely lost in the inactive center of chronic active lesions (N-P).
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wavelength correction on a spectrophotometer (Bio-Rad,
Hercules, CA).
Statistical analysis
Student’s t-test was applied to determine differences be-
tween PGC-1α- and mock transduced astrocytes with
regard to viability, ROS production and cytokine pro-
duction. 2-Way ANOVA with Bonferroni post-hoc test
was used to analyze the co-culture experiments and asses
differences between Prx3-, Trx2- and mock-transduced
astrocytes.
Results
Mitochondrial antioxidant expression in MS white matter
The early active lesion area in acute MS cases is charac-
terized by severe demyelination (Figure 1A), massive
microglial activation and the presence of densely packed
macrophages containing myelin degradation products
(Figure 1B) [33]. Late active MS lesions contain abun-
dant leukocyte infiltrates throughout the lesion area, but
lack PLP-positive macrophages (Figure 1C). Chronic ac-
tive lesions are characterized by a rim of MHC class II-
positive activated microglia and a demyelinated center
devoid of inflammatory cells (Figure 1D).
PGC-1α, Prx3 and Trx2 were weakly expressed in as-
trocytes in normal appearing white matter (NAWM)
(Figure 1E-G) and control white matter and no marked
differences were observed comparing the intensity and
cellular localization of PGC-1α, Prx3 and Trx2 immu-
nostainings in NAWM with control white matter (data
not shown). The expression of PGC-1α, Prx3 and Trx2
was strikingly upregulated in early active lesions compared
to surrounding NAWM and localized to astrocytes (ar-
rows) and oligodendrocytes (arrowheads) (Figure 1H-J).
PGC-1α, Prx3 and Trx2 immunoreactivity was also con-
sistently increased in late active lesions compared to
NAWM, albeit less pronounced compared to early active
lesions (Figure 1K-M). In late active lesions PGC-1α, Prx3
and Trx2 predominantly localized to cells with the mor-
phological appearance of reactive astrocytes. In contrast to
early active lesions, we did not find abundant oligodendro-
cyte expression of PGC-1α, Prx3 and Trx2 in late active
lesions. Expression levels of PGC-1α, Prx3 and Trx2 in
the inactive center of chronic active lesions were similar asobserved in the NAWM (Figure 1N-P). Immunofluores-
cent triple stainings with glial fibrillary acidic protein
(GFAP, astrocyte marker) and carbonic anhydrase II (CAII,
oligodendrocyte marker) confirmed the cellular localiza-
tion in astrocytes and oligodendrocytes (arrowhead) in
early active lesions (Figure 2A-C). In late active MS
lesions, PGC-1α (Figure 2D), Prx3 (Figure 2E) and Trx2
(Figure 2F) predominantly localized to astrocytes and to a
much lesser extent to oligodendrocytes (2G-I). Mitochon-
drial antioxidant enzymes are weakly expressed in axons
in active MS lesions (Additional file 3: Figure S1) and no
apparent changes were observed between patients and
controls (data not shown). Co-localization studies with the
mitochondrial protein porin indicate that outside the nu-
cleus, PGC-1α is expressed in mitochondria as described
previously (Additional file 3: Figure S1) [34].
Taken together, the expression of PGC-1α and the
mitochondrial antioxidant enzymes Prx3 and Trx2 is
strongly increased in astrocytes in active MS lesions. In
contrast, in the inactive center of chronic active demyeli-
nated lesions the expression of PGC-1α, Prx3 and Trx2
returned to levels similar to the NAWM.
Regulation and protective effect of astrocytic PGC-1α
under oxidative stress
To determine whether oxidative stress underlies the ob-
served increase in astrocytic PGC-1α and mitochondrial
antioxidant expression, human astrocytes were exposed
to 50 μM tert-butyl hydrogen peroxide (tbH2O2) for
24 hours. Exposure to ROS significantly increased gene
expression of Prx3, Trx2 and PGC-1α in human astro-
cytes (Figure 3A). Next, human astrocytes were stably
transduced with PGC-1α containing lentivirus (PGC-1α+
astrocytes) thereby increasing expression of PGC-1α and
its downstream targets Prx3 and Trx2 (Figure 3B). Over-
expression of PGC-1α markedly increased the resistance
of astrocytes against an oxidative attack (Figure 3C) and
completely abolished oxidative stress-induced intracellu-
lar ROS production (Figure 3D). In order to assess the
effect of PGC-1α upregulation in astrocytes on sur-
rounding cells, GFP+ neuronal cells were co-cultured
with mock-transduced or PGC-1α+ astrocytes and sub-
sequently stimulated with 200 μM tbH2O2 for 6 hours.
Neuronal cell death was significantly reduced when co-
cultured with PGC-1α+ astrocytes compared to mock
Figure 2 PGC-1alpha, Prx3 and Trx2 are mainly expressed in astrocytes. Triple immunofluorescent staining shows colocalization of PGC-1α
(A, red), Prx3 (B, red), Trx2 (C, red) with GFAP-positive astrocytes (green) and CAII-positive oligodendrocytes (blue) in early active lesions. In late
active lesions GFAP (red) positive cells colocalize with PGC-1α (D), Prx3 (E) and Trx2 (F). CAII positive oligodendrocytes (red, arrowheads) did not
colocalize with PGC-1α (G), Prx3 (H) and Trx2 (I) in late active lesions, whereas astrocyte like cells could be clearly distinguished (arrow).
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served neuroprotective effect of PGC-1α+ astrocytes was
not due to decreased astrocytic cell death in the PGC-1α+
astrocytes compared to mock astrocytes as GFP+ astro-
cytes co-cultured with GFP− neuroblastoma cells showed
virtually no cell death (Figure 3E).
As shown in Figure 3B, PGC-1α overexpression in as-
trocytes increased expression of Prx3 and Trx2, which
likely contributes to the protective effect of PGC-1α
against oxidative stress. Primary human astrocytes were
only limited available, therefore we used U373 astrocy-
toma cells to assess whether Prx3 and Trx2 overexpres-
sion resulted in increased resistance against oxidative
stress. Importantly, overexpression of PGC-1α in U373
cells showed similar protective effects as the PGC-1α+
astrocytes (Additional file 4: Figure S2). Overexpression
of Prx3 and Trx2 in U373 astrocyte-like cells reduced
ROS production and increased viability of astrocytes and
surrounding neurons upon treatment with tbH2O2
(Additional file 4: Figure S2). Taken together, our data
indicate that ROS induce upregulation of PGC-1α and
downstream mitochondrial antioxidants, which in turn
protects astrocytes and surrounding cells against ROS-
mediated cell death.PGC-1α+ astrocytes have a reduced inflammatory profile
Reactive astrocytes in MS are known to produce high
levels of the pro-inflammatory factors IL-6 and CCL2,
which stimulate astrogliosis, increase vascular activation
and enhance migration of leukocytes into the brain
[35-37]. Previous studies have shown that increased
PGC-1α expression can reduce the production of IL-6 and
CCL2 in skeletal muscle cells [38,39]. This prompted us to
investigate the role of PGC-1α on the expression of IL-6
and CCL2 in human astrocytes.
TNF-α and IFN-γ are present in high concentrations
in inflammatory MS lesions and treatment of astrocytes
with TNF-α and IFN-γ is a useful tool to create reactive
astrocytes in vitro [7,40,41]. Interestingly, our results show
that PGC-1α+ astrocytes express the pro-inflammatory
genes IL-6 and CCL2 at lower levels under basal condi-
tions and upon stimulation with TNF-α/IFN-γ compared
to mock transduced astrocytes (Figure 4A-B). Secretion of
IL-6 and CCL2 was also reduced in PGC-1α+ astrocytes
(Figure 4C-D). Next, we investigated whether PGC-1α
overexpression decreased cytokine-induced ROS produc-
tion. Notably, TNF-α/IFN-γ-mediated ROS production
was significantly reduced in PGC-1α+ astrocytes compared
to mock transduced astrocytes (Figure 4E). Our findings
Figure 3 Regulation and protective effects of astrocytic PGC-1alpha. Treatment of human astrocytes with tbH2O2 increased mRNA expression
levels of PGC-1α, Prx3 and Trx2 (A). Western blot analysis illustrates that lentiviral overexpression of PGC-1α increases PGC-1α, Prx3 and Trx2 expression
(B). PGC-1α+ astrocytes were more resistant to tbH2O2 induced cell death (C) and produced less ROS compared to mock-transduced astrocytes (D).
SHSY5Y cells were better protected against tbH2O2 induced cell death when co-cultured with PGC-1α+overexpressing astrocytes compared to mock-
transduced astrocytes (E). GFP+ astrocytes co-cultured with SHSY5Y cells did not show reduced viability after tbH2O2 treatment (E). *P < 0.05, **P < 0.01,
***P < 0.001 as determined by students T-test for figure A, C, D and with two-way ANOVA with post-hoc Bonferroni correction for Figure E.
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redox metabolism, exerts a profound effect on the inflam-
matory profile of astrocytes.
Discussion
In the present study we show that the expression of the
transcription co-factor proliferator-activated receptorgamma coactivator 1-alpha (PGC-1α) and downstream
mitochondrial antioxidant enzymes peroxiredoxin-3 (Prx3)
and thioredoxin-2 (Trx2) is markedly increased in astro-
cytes in active multiple sclerosis (MS) lesions. Our in vitro
data provide evidence that overexpression of PGC-1α pro-
tects human astrocytes against oxidative stress and re-
duces intracellular ROS production. Moreover, co-culture
Figure 4 Inflammatory profile of PGC-1alpha overexpressing astrocytes. PGC-1α+ astrocytes expressed less IL-6 (A) and CCL2 (B) mRNA
under normal conditions and after 24 hr treatment with TNFα/IFNγ compared to mock-transduced astrocytes. Secretion of IL-6 (C) and CCL2
(D) by astrocytes as measured by ELISA is reduced in PGC-1α+ astrocytes. TNFα/IFNγ increased ROS production in mock-transduced astrocytes
but not in PGC-1α expressing astrocytes (E). *P < 0.05, **P < 0.01, ***P < 0.001 as determined by students T-test.
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in astrocytes protects neurons from ROS-induced cell
death. Finally, we demonstrate that PGC-1α overexpres-
sion reduces the production of astrocyte-derived inflam-
matory molecules.
ROS unambiguously play a cardinal role in MS path-
ology as recent studies demonstrate a clear association
between inflammation-derived ROS, mitochondrial (dys)
function and neurodegeneration [12]. Since little is
known about the distribution and functional role of
mitochondrial enzymes, we set out to investigate the ex-
pression of PGC1-α and its downstream targets Prx3
and Trx2 in a large selection of white matter MS lesions.
In early active MS lesions, which represent the initial
phase of MS lesions, we found a striking increase in the
expression of PGC1-α, Prx3 and Trx2 in both astrocytes
and oligodendrocytes compared to NAWM and controltissue [42]. Our in vitro experiments demonstrated that
astrocytes strongly upregulate PGC1-α and mitochon-
drial antioxidants upon exposure to ROS, which is in
line with previous studies describing ROS-induced
PGC1-α expression in mouse muscle and embryonic
mesenchymal stem cells [43,44]. This likely represents a
protective response to the local oxidative milieu. In fact,
we show that overexpression of PGC-1α or mitochon-
drial antioxidants protects astrocytes from ROS-induced
cell death, which corroborates previous studies using
different cell types and experimental animal models
[21,45-47]. In late active MS lesions, enhanced PGC1-α,
Prx3 and Trx2 immunoreactivity was mainly observed in
astrocytes, not oligodendrocytes. This finding suggests
that surviving oligodendrocytes may lose their ability to
express adequate levels of mitochondrial antioxidants in
time, making them more vulnerable to ROS-induced cell
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http://www.actaneurocomms.org/content/2/1/170death. Notably, oligodendrocyte loss is a key feature of
inflammatory MS lesions, whereas astrocytes generally
survive. Our findings are in line with previous data from
our group in which we showed that astrocytes effectively
induce cytoplasmic antioxidant levels in late active MS
lesions [10]. Besides oligodendrocytes, axons represent
the main victims of the oxidative attack in inflammatory
lesions [25]. Remarkably, similar to previous observa-
tions for cytoplasmic antioxidants, we found no evident
increase in mitochondrial antioxidant defence mecha-
nisms in axons in any stage of MS pathology [10]. A
likely explanation is that the distance between the cell
body, where PGC-1α induces expression of mitochon-
drial antioxidants, and the affected axon is too large for
a timely and efficient antioxidative response. Moreover,
we previously showed that PGC-1α, Prx3 and Trx2 are
decreased in cortical neurons of MS patients, suggesting
that reduced PGC-1α in cortical neuronal cell bodies
might contribute to the lack of mitochondrial antioxidantFigure 5 Graphical abstract. Macrophages are attracted by CCL2 and infiltr
and TNF-α and IFN-γ. This will lead to mitochondrial stress, resulting in more m
Increased amounts of ROS induce astrocytic PGC-1α, which increases mitocho
expression of PGC-1α, Prx3 or Trx2 protects astrocytes and surrounding neuro
Interestingly, PGC-1α can reduce CCL2 and IL-6 production and TNF-α/IFN-γ in
increased astrocytic PGC-1alpha can reduce ROS and inflammation in MS lesioinduction in demyelinated axons [22]. Taken together, the
relative inability of axons and oligodendrocytes to increase
their mitochondrial antioxidative capacity in response to
an oxidative attack likely contributes to the extensive oxi-
dative damage of axons and oligodendrocytes and subse-
quent cell death in MS lesions.
Loss of PGC-1α in cultured neurons induces intracel-
lular ROS production and the susceptibility to ROS-
induced cell death [22]. In this study we show for the
first time that enhanced astrocytic expression of PGC-1α
and mitochondrial antioxidants is able to protect adja-
cent neurons from exogenous ROS in vitro. A potential
explanation for the intriguing neuroprotective effect is
that astrocytes can shuttle antioxidants to neurons,
thereby enhancing neuronal antioxidant capacity. This
has been shown for glutathione, but it remains unknown
whether Prx3 and Trx2 are also secreted by astrocytes
[48,49]. Interestingly, PGC-1α can also stimulate the pro-
duction of enzymes involved in glutathione biosynthesisate the brain, phagocytose myelin and produce high amounts of ROS
itochondrial ROS production contributing to axonal degeneration.
ndrial antioxidant capacity via upregulation of Prx3 and Trx2. Increased
ns not only from mitochondrial stress but also against exogenous ROS.
duced ROS production, thereby dampening inflammation. Thus
ns which protects surrounding axons and neurons.
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astroglial Prx3 or Trx2 alone is sufficient to protect sur-
rounding neurons against an oxidative insult. The precise
mechanism how enhanced levels of astroglial PGC-1α and
downstream mitochondrial antioxidant enzymes protect
neighbouring cells warrants future research, but astrocytes
may scavenge extracellular ROS and by preserving their
mitochondrial function during oxidative stress, astrocytes
remain able to provide support to adjacent neurons.
Nonetheless, neuro-axonal damage is profound in (early)
active MS lesions indicating that the increase in astroglial
mitochondrial antioxidants is not sufficient to protect all
neighbouring axonal structures and cells [25].
PGC-1α regulates the transcription of a broad array of
genes and is a key player in mitochondrial biogenesis,
consequently it is conceivable that the protective effects
of enhanced PGC-1α levels extend beyond increased
mitochondrial antioxidant production [24]. Since PGC-1α
has such widespread effects and evidence for an intricate
relationship between cellular metabolism and inflamma-
tion is mounting, we were interested whether astroglial
PGC-1α was able to influence the production of inflam-
matory mediators [51,52]. In inflammatory MS lesions, re-
active astrocytes are known to produce high amounts of
IL-6 and CCL2 thereby contributing to the ongoing in-
flammation [35,36]. Interestingly, PGC-1α overexpression
strongly reduced the production of astrocytic IL-6, CCL2
and ROS upon treatment with key pro-inflammatory me-
diators. The anti-inflammatory effects of PGC-1α could be
mediated by PGC-1α-induced PPAR signalling which is
known to reduce IL-6 and CCL2 production by astrocytes,
however future studies are needed to elucidate the anti-
inflammatory properties of PGC-1α [53].
This study provides novel insights in the protective
properties of reactive astrocytes. We previously showed
that reactive astrocytes produce both pro- and anti-
inflammatory mediators, but they are vital for tissue repair
since ablation of astrocyte activation enhances CNS dam-
age in various experimental models [6,7,54-56]. Thus,
therapies aimed at augmenting the production and activity
of mitochondrial antioxidants in neurons, but also in
astrocytes, represent an interesting strategy to restore
mitochondrial function and combat neurodegeneration.
Activation of the PGC-1α pathway is of particular interest
since this will not only boost the (mitochondrial) antioxi-
dants machinery, but, in addition, also promotes expres-
sion of a variety of proteins involved in energy metabolism
and suppresses inflammation [26]. Several studies have
shown that resveratrol and progesterone, both known to
activate PGC-1α, are neuroprotective and reduce clinical
symptoms in experimental autoimmune encephalitis (EAE)
[57-59]. Interestingly, overexpression of sirtuin 1 (Sirt1), a
direct activator of PGC-1α, is also neuroprotective and re-
duces clinical symptoms in EAE [60].Conclusion
In conclusion, we have shown increased PGC-1α and
downstream mitochondrial antioxidant enzyme expression
in astrocytes in inflammatory MS lesions. Overexpression
of PGC-1α in primary human astrocytes attenuates intra-
cellular ROS production and protects astrocytes as well as
surrounding cells from ROS-mediated cell death. Moreover,
we provide evidence that PGC-1α limits the production of
astrocyte-derived inflammatory molecules (Figure 5).
Hence, activation of the PGC-1α pathway represents an
attractive approach to limit both inflammation and oxida-
tive stress, two key features of MS pathogenesis.
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